Synonym
BAY-41-8543; BAY418543; BAY41-8543; UNII-323T2C09SG;
IUPAC/Chemical Name
2-(1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl)-5-morpholinopyrimidine-4,6-diamine
InChi Key
AQYFUZRYBJBAGZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H21FN8O/c22-15-6-2-1-4-13(15)12-30-21-14(5-3-7-25-21)16(28-30)20-26-18(23)17(19(24)27-20)29-8-10-31-11-9-29/h1-7H,8-12H2,(H4,23,24,26,27)
SMILES Code
c1ccc(c(c1)Cn2c3c(cccn3)c(n2)c4nc(c(c(n4)N)N5CCOCC5)N)F
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
420.44
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Stancu B, Krämer S, Loof T, Mika A, Amann K, Neumayer HH, Peters H. Soluble guanylate cyclase stimulator BAY 41-8543 and female sex ameliorate uremic aortic remodeling in a rat model of mild uremia. J Hypertens. 2015 Sep;33(9):1907-20; discussion 1921. doi: 10.1097/HJH.0000000000000648. PubMed PMID: 26176653.
2: Watts JA, Gellar MA, Fulkerson MB, Kline JA. A soluble guanylate cyclase stimulator, BAY 41-8543, preserves right ventricular function in experimental pulmonary embolism. Pulm Pharmacol Ther. 2013 Apr;26(2):205-11. doi: 10.1016/j.pupt.2012.10.009. Epub 2012 Nov 7. PubMed PMID: 23142020.
3: Lasker GF, Pankey EA, Allain AV, Dhaliwal JS, Stasch JP, Murthy SN, Kadowitz PJ. Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat. J Sex Med. 2013 Mar;10(3):704-18. doi: 10.1111/j.1743-6109.2012.02912.x. Epub 2012 Sep 18. PubMed PMID: 22989320; PubMed Central PMCID: PMC3594361.
4: Watts JA, Gellar MA, Fulkerson MB, Kline JA. Pulmonary vascular reserve during experimental pulmonary embolism: effects of a soluble guanylate cyclase stimulator, BAY 41-8543. Crit Care Med. 2011 Dec;39(12):2700-4. doi: 10.1097/CCM.0b013e318226678e. PubMed PMID: 21705882.
5: Badejo AM Jr, Nossaman VE, Pankey EA, Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD, Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1153-9. doi: 10.1152/ajpheart.01101.2009. Epub 2010 Jul 16. PubMed PMID: 20639220; PubMed Central PMCID: PMC2957355.
6: Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol. 2002 Jan;135(2):344-55. PubMed PMID: 11815369; PubMed Central PMCID: PMC1573146.
7: Stasch JP, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Minuth T, Perzborn E, Schramm M, Straub A. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol. 2002 Jan;135(2):333-43. PubMed PMID: 11815368; PubMed Central PMCID: PMC1573147.
